（文章来源：证券日报） 证券日报网讯 1月19日，安路科技在互动平台回答投资者提问时表示，公司始终坚持稳健经营，致力于 为所有投资者创造价值。股东减持其持有的股份属于正常的资金需求或投资决策，不会影响公司长期的 经营和发展。公司也将督促股东严格遵守相关规定，告知并提交减持计划及后续进展情况。在合规范围 内，公司都将尊重并理解广大投资者的决策，股东减持的具体情况请关注公司披露的减持相关公告。 ...

Core Viewpoint - Shanghai Kehui Equity Investment Center (Limited Partnership), a shareholder holding 6.92% of Huaxin Environmental Protection, plans to reduce its stake by up to 1.7652 million shares within three months after 15 trading days from the announcement date, representing 0.58% of the company's total share capital and 0.59% of the total share capital excluding repurchased shares [1] Summary by Relevant Categories Shareholder Actions - Shanghai Kehui Equity Investment Center intends to reduce its holdings by a maximum of 1.7652 million shares [1] - The planned reduction accounts for 0.58% of the total share capital of Huaxin Environmental Protection [1] - The current holding of Shanghai Kehui is 20.9652 million shares, which is 6.92% of the total share capital [1] Company Capital Structure - The total share capital of Huaxin Environmental Protection, excluding repurchased shares, is impacted by the planned reduction, with the reduction representing 0.59% of this adjusted total [1] - The current shareholding percentage of Shanghai Kehui, when excluding repurchased shares, is 7.04% [1]

1月14日，立高食品发布公告称，近日收到到持股 5%以上股东陈和军出具的《股份减持计划告知函》，陈和军因个人资金需求，计划于本减持计划公告之 日起15个交易日后的三个月内以集中竞价交易、大宗交易的方式减持公司股份不超过2,650,000股（含本数），即不超过剔除回购专用账户股份数量后公司总 股本的1.5903%。 按照立高食品14日股价收盘的45元/股价格计算，陈和军此次减持套现金额约为1.19亿元。 事实上，这也不是立高食品股东第一次套现。2025年以来，随着立高食品股价持续走高，股东也多次趁机套现。 据报道，2025年8月，立高食品发布公告称，股东上海立高兴企业管理咨询合伙企业（有限合伙）、上海立高创企业管理咨询合伙企业（有限合伙）系公司 股东和员工持股平台，为控股股东、实际控制人彭裕辉的一致行动人，拟合计减持不超2.47%公司股份，套现近2亿元。 公开资料显示，立高食品是冷冻烘焙龙头企业，主营业务是冷冻烘焙食品及烘焙食品原料的研发、生产和销售，主要产品是冷冻烘焙食品、烘焙食品原材 料、仓储运输服务。 此外，立高食品也是山姆网红产品麻薯的长期供应商。2025年前三季度，立高食品营收为31.45亿元，同比增 ...

Group 1 - The company announced that the "Haomei Convertible Bonds" will pay the fourth-year interest on January 26, 2026, at a rate of 1.60%, amounting to 16.00 RMB for every 10 bonds [2][12] - The interest payment period is from January 24, 2025, to January 23, 2026, with the interest payment date and ex-dividend date both set for January 26, 2026 [3][12] - The bondholders registered by the close of trading on January 23, 2026, will be eligible for the interest payment [3][12] Group 2 - The company issued 8.24 million convertible bonds, with a total issuance amount of 824 million RMB, which were listed on March 4, 2022 [4] - The bonds have a maturity period from January 24, 2022, to January 23, 2028, with a scheduled annual interest payment [4][6] - The interest rates for the bonds increase over time, starting from 0.30% in the first year to 3.00% in the sixth year [5] Group 3 - The company has a credit rating of "AA-" for the bonds, with a stable outlook as per the evaluation by Zhongzheng Pengyuan Credit Rating Co., Ltd. [11] - The bonds are unsecured, and the company will not provide any guarantees for the repayment of the principal and interest [11] - The bonds' interest income tax obligations will be handled differently based on the type of bondholder, with specific provisions for individual investors and qualified foreign institutional investors [13][16] Group 4 - The company reported that a major shareholder, Shanghai Chiyao Investment Co., Ltd., completed a share reduction plan, reducing its stake from 5.3217% to 4.99999% [19][20] - The reduction was executed through centralized bidding, with a total of 1,100,000 shares sold within the specified period [20][21] - The share reduction does not affect the company's control structure or governance [22]

Group 1 - The core point of the announcement is that Zhida Venture Capital, a shareholder of Weisi Medical, plans to reduce its stake in the company by selling up to 287.31 million shares, which represents 3% of the total share capital [1] - Zhida Venture Capital currently holds 6.7583 million shares, accounting for 7.06% of the total share capital, and is considered a concerted actor with the actual controller Wang Zhiyu [1] - The reduction plan will take place from February 9, 2026, to May 8, 2026, through centralized bidding and block trading, with a maximum of 95.77 million shares to be sold via centralized bidding and 191.54 million shares via block trading [1] Group 2 - The reason for the share reduction is stated as a need for personal funds, and there is uncertainty regarding the implementation of the reduction plan [1] - It is confirmed that the completion of this share reduction will not result in a change of control of the company [1]

Core Viewpoint - The company, He Shi Eye Hospital (301103.SZ), announced that its shareholder, Advanced Manufacturing Industry Investment Fund (Limited Partnership), plans to reduce its shareholding by up to 3.106074 million shares, representing 1.97% of the total share capital of the company [1] Summary by Relevant Categories Shareholder Actions - The Advanced Manufacturing Industry Investment Fund intends to reduce its holdings from February 7, 2026, to May 6, 2026, through centralized bidding and block trading on the stock exchange [1] - The planned reduction accounts for 2% of the total share capital after excluding shares held in the repurchase special securities account [1]

金科环境公告称，截至公告披露日，持股5%以上股东利欣水务持有公司股份867.52万股，占总股本 7.05%。因自身资金需求，利欣水务计划自2026年2月9日至5月8日，通过集中竞价交易方式减持不超 102.52万股，即不超总股本0.83%，减持价格按市场价确定。此次减持计划存在实施的不确定性，不会 导致公司控制权变更。 ...

Core Viewpoint - The company, Lai Shen Tong Ling, received a warning letter from the Jiangsu Securities Regulatory Bureau regarding Eurostar Diamond (Shanghai) Co., Ltd. for failing to disclose shareholder holding matters accurately, violating regulations related to the management of listed company acquisitions [2][4]. Group 1: Regulatory Actions - Eurostar Diamond, as a significant shareholder of Lai Shen Tong Ling, did not disclose that it was holding shares on behalf of Eurostar Diamond International S.A., which owns 41.66% of Eurostar Diamond [4]. - The Jiangsu Securities Regulatory Bureau issued a warning letter to Eurostar Diamond for this non-disclosure, which is recorded in the securities and futures market integrity archive [4][5]. Group 2: Company Performance - Lai Shen Tong Ling reported a revenue of 1.2 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 35.95%, and a net profit attributable to shareholders of 69.09 million yuan, marking a turnaround from losses [5][6]. - The growth in revenue is attributed mainly to increased income from gold-inlaid diamond jewelry [6]. Group 3: Shareholder Actions - Several shareholders holding more than 5% of Lai Shen Tong Ling have announced plans to reduce their holdings in the past six months [7]. - For instance, Ningbo Ningju Asset Management Center (Limited Partnership) plans to reduce its stake by up to 1% of the total share capital due to personal funding needs [7].

Core Viewpoint - The major shareholder, Guangzhou Unified Enterprise Co., Ltd., has reduced its stake in Yantai Northern Andeli Juice Co., Ltd. by 1% through a share reduction plan, impacting the overall shareholding structure of the company [1][2]. Group 1: Shareholder Information - The major shareholder involved in the reduction is Guangzhou Unified Enterprise Co., Ltd., along with its concerted actions, Chengdu Unified Enterprise Food Co., Ltd., and Unified Enterprise China Holdings Ltd. [1] - After the reduction, the total shares held by Guangzhou Unified and its concerted actions decreased from 63,983,040 shares to 62,503,040 shares, resulting in a shareholding percentage drop from 19.15% to 18.70% [1]. Group 2: Details of the Share Reduction - The share reduction occurred between January 15 and January 16, 2026, with a total of 1,480,000 shares sold at an average price of 38.94 yuan per share [1]. - This reduction is part of a previously disclosed share reduction plan and does not trigger a mandatory tender offer or involve any changes in the source of funds [2]. Group 3: Compliance and Regulations - The share reduction complies with relevant laws and regulations, including the Securities Law of the People's Republic of China and the Management Measures for the Reduction of Shares by Shareholders of Listed Companies [3]. - The company will continue to monitor the shareholder's compliance with the reduction plan and ensure timely disclosure of relevant information to investors [3].

Core Viewpoint - The major shareholder OAP III (HK) Limited plans to reduce its stake in Sichuan Baili Tianheng Pharmaceutical Co., Ltd. due to personal funding needs, intending to sell up to 4,128,738 shares, which represents no more than 1.00% of the company's total share capital [1][2]. Shareholder Information - As of the announcement date, OAP III (HK) Limited holds 28,527,171 shares, accounting for 6.91% of the total share capital of the company [1]. - The shares to be sold were acquired prior to the company's initial public offering and have been released from restrictions as of January 8, 2024 [1]. Reduction Plan Details - The reduction will occur through centralized bidding within three months after the announcement, starting fifteen trading days from the disclosure date [1]. - The selling price will be determined based on the market price at the time of the sale, and it will not be lower than the initial public offering price [2]. Compliance and Commitments - OAP III (HK) Limited has no other arrangements regarding the reduction and has made prior commitments regarding its shareholding, including not transferring shares within 12 months of the company's listing [3][4]. - The company has agreed to compensate for any losses incurred due to violations of these commitments [4][5]. Regulatory Compliance - The planned reduction complies with relevant laws and regulations, including the Shanghai Stock Exchange's guidelines for shareholder reductions [8].